S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
My No. 1 dividend stock for a LIFETIME of income. (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:AMED

Amedisys - AMED Stock Forecast, Price & News

$93.58
+1.64 (+1.78%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$91.73
$94.20
50-Day Range
$80.12
$97.00
52-Week Range
$79.30
$179.91
Volume
316,560 shs
Average Volume
434,556 shs
Market Capitalization
$3.04 billion
P/E Ratio
25.22
Dividend Yield
N/A
Price Target
$128.25

Amedisys MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
37.0% Upside
$128.25 Price Target
Short Interest
Bearish
5.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.50mentions of Amedisys in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.07%
From $4.83 to $4.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

55th out of 1,026 stocks

Home Health Care Services Industry

4th out of 9 stocks

AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

Predict These Market Breakouts with A.I.
We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. pixel
Free Stock Analysis Report: See the Right Way to Analyze Stocks
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
Amedisys: No Change To Thesis, Retain Hold
Amedisys Names Scott Ginn Acting Chief Operating Officer
Amedisys reaffirms FY22 guidance
Amedisys Third Quarter 2022 Earnings: Misses Expectations
Amedisys Statement on CY 2023 Home Health Final Rule
Expert Ratings for Amedisys
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
11/02/2021
Today
2/08/2023
Next Earnings (Confirmed)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$128.25
High Stock Price Forecast
$190.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+37.0%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$209.07 million
Pretax Margin
7.47%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$8.55 per share
Book Value
$29.95 per share

Miscellaneous

Free Float
31,810,000
Market Cap
$3.04 billion
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Paul B. K. Kusserow
    Chairman & Chief Executive Officer
  • Scott G. GinnScott G. Ginn
    EVP, Chief Operating & Financial Officer
  • Michael P. NorthMichael P. North
    Chief Information Officer
  • Denise M. BohnertDenise M. Bohnert
    Chief Compliance Officer
  • Nick Muscato
    Chief Strategy Officer













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2023?

15 brokers have issued 12-month price objectives for Amedisys' stock. Their AMED share price forecasts range from $85.00 to $190.00. On average, they expect the company's stock price to reach $128.25 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2023?

Amedisys' stock was trading at $83.54 at the start of the year. Since then, AMED shares have increased by 12.0% and is now trading at $93.58.
View the best growth stocks for 2023 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our AMED earnings forecast
.

How can I listen to Amedisys' earnings call?

Amedisys will be holding an earnings conference call on Thursday, February 16th at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735891".

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) released its quarterly earnings results on Tuesday, November, 2nd. The health services provider reported $1.53 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.16. The health services provider had revenue of $553.49 million for the quarter, compared to analyst estimates of $568.55 million. Amedisys had a trailing twelve-month return on equity of 16.00% and a net margin of 5.45%. During the same quarter in the previous year, the firm earned $2.24 EPS.

How will Amedisys' stock buyback program work?

Amedisys announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY 2022 earnings guidance on Sunday, December, 18th. The company provided earnings per share (EPS) guidance of $4.82-$4.93 for the period, compared to the consensus estimate of $4.87. The company issued revenue guidance of $2.22 billion-$2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a variety of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (4.70%), Boston Partners (1.00%), Fort Washington Investment Advisors Inc. OH (0.44%), Leeward Investments LLC MA (0.42%), Envestnet Asset Management Inc. (0.36%) and Handelsbanken Fonder AB (0.27%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $93.58.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $3.04 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $3.71 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 21,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 2/9/2023 by MarketBeat.com Staff